[
  {
    "ts": "2026-01-29T00:23:00+00:00",
    "headline": "This Could Be 1 of the Best Pharmaceutical Stock-Buying Opportunities I've Seen in Years",
    "summary": "After a years-long revenue drought, there's a light at the end of the tunnel.",
    "url": "https://www.fool.com/investing/2026/01/28/this-could-be-1-of-the-best-pharmaceutical-stock-b/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "20e78104-c2ef-3257-ae69-c6f6b2cb62e3",
      "content": {
        "id": "20e78104-c2ef-3257-ae69-c6f6b2cb62e3",
        "contentType": "STORY",
        "title": "This Could Be 1 of the Best Pharmaceutical Stock-Buying Opportunities I've Seen in Years",
        "description": "",
        "summary": "After a years-long revenue drought, there's a light at the end of the tunnel.",
        "pubDate": "2026-01-29T00:23:00Z",
        "displayTime": "2026-01-29T00:23:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/12284f4342a923cb427b9a8384471897",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "A pharmacist fills a prescription.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/VssVsrudPoJbklYmB6FzwQ--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/12284f4342a923cb427b9a8384471897.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_Y3WYznXgu._B5kexNUqHA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/12284f4342a923cb427b9a8384471897.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/01/28/this-could-be-1-of-the-best-pharmaceutical-stock-b/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/could-1-best-pharmaceutical-stock-002300269.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-29T07:07:40+00:00",
    "headline": "Pfizer Inks $530M Deal for Novavax Matrix-M Adjuvant Technology to Boost Vaccine Pipeline",
    "summary": "Pfizer Inc. (NYSE:PFE) is one of the best inexpensive stocks to buy now. On January 20, Novavax announced a non-exclusive licensing agreement with Pfizer, granting the pharmaceutical giant access to its Matrix-M adjuvant tech. This technology is designed to boost immune responses to vaccines and will be utilized by Pfizer for up to two infectious […]",
    "url": "https://finance.yahoo.com/news/pfizer-inks-530m-deal-novavax-070740991.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "683d7593-e9bf-3fbf-b639-76f45d021516",
      "content": {
        "id": "683d7593-e9bf-3fbf-b639-76f45d021516",
        "contentType": "STORY",
        "title": "Pfizer Inks $530M Deal for Novavax Matrix-M Adjuvant Technology to Boost Vaccine Pipeline",
        "description": "",
        "summary": "Pfizer Inc. (NYSE:PFE) is one of the best inexpensive stocks to buy now. On January 20, Novavax announced a non-exclusive licensing agreement with Pfizer, granting the pharmaceutical giant access to its Matrix-M adjuvant tech. This technology is designed to boost immune responses to vaccines and will be utilized by Pfizer for up to two infectious […]",
        "pubDate": "2026-01-29T07:07:40Z",
        "displayTime": "2026-01-29T07:07:40Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/101b148d88f043f017180ca8b31d9a4a",
          "originalWidth": 1920,
          "originalHeight": 1281,
          "caption": "Pfizer Inks $530M Deal for Novavax Matrix-M Adjuvant Technology to Boost Vaccine Pipeline",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/klOIJuPmSNUuqUttRqYcyw--~B/aD0xMjgxO3c9MTkyMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/insidermonkey.com/101b148d88f043f017180ca8b31d9a4a.cf.webp",
              "width": 1920,
              "height": 1281,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NNO5eYVXOnUsR4MHY_ZoVg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/101b148d88f043f017180ca8b31d9a4a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-inks-530m-deal-novavax-070740991.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-inks-530m-deal-novavax-070740991.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NVAX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-29T12:23:00+00:00",
    "headline": "3 High-Yield Stocks to Buy Hand Over Fist in January",
    "summary": "If you like dividend stocks, here's a high yielder, a Dividend King, and a turnaround story to consider as January comes to a close.",
    "url": "https://www.fool.com/investing/2026/01/29/3-high-yield-stocks-to-buy-hand-over-fist-in-jan/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "e0f0d22b-ddea-3a1b-995c-ab6b9d2df4e0",
      "content": {
        "id": "e0f0d22b-ddea-3a1b-995c-ab6b9d2df4e0",
        "contentType": "STORY",
        "title": "3 High-Yield Stocks to Buy Hand Over Fist in January",
        "description": "",
        "summary": "If you like dividend stocks, here's a high yielder, a Dividend King, and a turnaround story to consider as January comes to a close.",
        "pubDate": "2026-01-29T12:23:00Z",
        "displayTime": "2026-01-29T12:23:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/2a381d22fc1b9c9fa1235661635fa07c",
          "originalWidth": 1400,
          "originalHeight": 650,
          "caption": "A line of 100 dollar bills planted in the ground.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/oLaEzPmeidxzPmFg9P1qbQ--~B/aD02NTA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/2a381d22fc1b9c9fa1235661635fa07c.cf.webp",
              "width": 1400,
              "height": 650,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qeIl9BLpQcm4XLntj4NwSA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/2a381d22fc1b9c9fa1235661635fa07c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/01/29/3-high-yield-stocks-to-buy-hand-over-fist-in-jan/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/3-high-yield-stocks-buy-122300668.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "O"
            },
            {
              "symbol": "PG"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-29T14:50:00+00:00",
    "headline": "Carbapenem-resistant Enterobacteriaceae Infection Market - A Global and Regional Analysis: Focus Country and Regional Analysis, 2025-2035",
    "summary": "The global carbapenem-resistant Enterobacteriaceae (CRE) infection market is experiencing robust growth due to the rising prevalence of multidrug-resistant Gram-negative infections and heightened awareness of antimicrobial resistance. Key drivers include the approval of next-generation antibiotics like Cefiderocol and institutional support in regions like North America. Increased healthcare spending and advanced therapeutic demand bolster market expansion from 2025-2035. However, high treatment",
    "url": "https://finance.yahoo.com/news/carbapenem-resistant-enterobacteriaceae-infection-market-145000270.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "35692a65-fce1-323c-8845-1c9017c4f63c",
      "content": {
        "id": "35692a65-fce1-323c-8845-1c9017c4f63c",
        "contentType": "STORY",
        "title": "Carbapenem-resistant Enterobacteriaceae Infection Market - A Global and Regional Analysis: Focus Country and Regional Analysis, 2025-2035",
        "description": "",
        "summary": "The global carbapenem-resistant Enterobacteriaceae (CRE) infection market is experiencing robust growth due to the rising prevalence of multidrug-resistant Gram-negative infections and heightened awareness of antimicrobial resistance. Key drivers include the approval of next-generation antibiotics like Cefiderocol and institutional support in regions like North America. Increased healthcare spending and advanced therapeutic demand bolster market expansion from 2025-2035. However, high treatment",
        "pubDate": "2026-01-29T14:50:00Z",
        "displayTime": "2026-01-29T14:50:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc",
          "originalWidth": 480,
          "originalHeight": 58,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_MlAqEncKPaKK77zrkRGmQ--~B/aD01ODt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 480,
              "height": 58,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/caWFqk489OEmv3xI33JamQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/carbapenem-resistant-enterobacteriaceae-infection-market-145000270.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/carbapenem-resistant-enterobacteriaceae-infection-market-145000270.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-29T14:15:02+00:00",
    "headline": "Ahead of Pfizer (PFE) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics",
    "summary": "Get a deeper insight into the potential performance of Pfizer (PFE) for the quarter ended December 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.",
    "url": "https://finance.yahoo.com/news/ahead-pfizer-pfe-q4-earnings-141502872.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "92c5c5cd-d3d6-3b68-9ea6-e4d5240b119d",
      "content": {
        "id": "92c5c5cd-d3d6-3b68-9ea6-e4d5240b119d",
        "contentType": "STORY",
        "title": "Ahead of Pfizer (PFE) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics",
        "description": "",
        "summary": "Get a deeper insight into the potential performance of Pfizer (PFE) for the quarter ended December 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.",
        "pubDate": "2026-01-29T14:15:02Z",
        "displayTime": "2026-01-29T14:15:02Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/c2fdcaac033e049c74f38d188afcc9f9",
          "originalWidth": 900,
          "originalHeight": 600,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ynQsYX5ACHYPVbgtuT.Zxg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/c2fdcaac033e049c74f38d188afcc9f9.cf.webp",
              "width": 900,
              "height": 600,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fz_9jpPkz.3eCTXvWlvRfQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/c2fdcaac033e049c74f38d188afcc9f9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/ahead-pfizer-pfe-q4-earnings-141502872.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/ahead-pfizer-pfe-q4-earnings-141502872.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-29T21:11:29+00:00",
    "headline": "Pfizer Balances Vaccine Expansion And Drug Discounts With Novavax And TrumpRx",
    "summary": "Pfizer (NYSE:PFE) has entered a non exclusive licensing agreement with Novavax for access to its Matrix-M adjuvant technology. The company is also participating in the White House TrumpRx initiative, offering substantial discounts on several drugs as part of a federal push on pricing. For you as an investor, this puts NYSE:PFE at the intersection of two important themes in healthcare: vaccines and drug affordability. Matrix-M is designed to boost immune response in vaccines, and access to...",
    "url": "https://finance.yahoo.com/news/pfizer-balances-vaccine-expansion-drug-211129146.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "c2ccb8dd-3d52-308a-9dad-41396b6dfae4",
      "content": {
        "id": "c2ccb8dd-3d52-308a-9dad-41396b6dfae4",
        "contentType": "STORY",
        "title": "Pfizer Balances Vaccine Expansion And Drug Discounts With Novavax And TrumpRx",
        "description": "",
        "summary": "Pfizer (NYSE:PFE) has entered a non exclusive licensing agreement with Novavax for access to its Matrix-M adjuvant technology. The company is also participating in the White House TrumpRx initiative, offering substantial discounts on several drugs as part of a federal push on pricing. For you as an investor, this puts NYSE:PFE at the intersection of two important themes in healthcare: vaccines and drug affordability. Matrix-M is designed to boost immune response in vaccines, and access to...",
        "pubDate": "2026-01-29T21:11:29Z",
        "displayTime": "2026-01-29T21:11:29Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QSfydsi7Q.1zNEN99DbEyw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hi2p7oczHh8yTJraqZcczg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-balances-vaccine-expansion-drug-211129146.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-balances-vaccine-expansion-drug-211129146.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NVAX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]